Drug Profile
Research programme: adipose-derived stem cell therapeutics - American CryoStem Corporation/Rutgers
Alternative Names: ADSC therapeuticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator American CryoStem Corporation; Rutgers
- Class Cytokines; Extracellular matrix proteins; Growth factors; Stem cell factors; Stem cell therapies; Tissue extracts
- Mechanism of Action Cell replacements; Cytokine stimulants; Growth stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic wounds; Skin ulcer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Chronic-wounds in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Skin-ulcer in USA (Parenteral)
- 14 May 2013 American CryoStem and Rutgers, the State University of New Jersey, sign a Material Transfer Agreement to research, develop and commercialise adipose-derived stem cells (ADSCs) in the US for Chronic wounds and Skin ulcers